Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05743049 · ClinicalTrials.gov registry record
Collection of Circulating Biomarkers in Pancreatic Cancer
A clinical trial of Pancreas Cancer, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT05743049: Recruiting study of Pancreas Cancer, sponsored by Abramson Cancer Center at Penn Medicine.
NCT05743049 is a study of Pancreas Cancer that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 30 participants, below the 907-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05743049, a study of Pancreas Cancer, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This protocol will involve collection of blood samples from patients with a diagnosis of pancreatic adenocarcinoma for evaluation of circulating biomarkers.
Conditions Studied
Interventions
- OTHER Obtaining blood for analysis of various circulating biomarkers
Study Locations (1)
Pennsylvania
- Abramson Cancer Center at University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-02-27 |
| Est. Completion | 2028-01-15 |
What NCT05743049 shows while recruiting
NCT05743049 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 907-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Pancreas Cancer appearing as the primary indexed condition, and to 1 intervention - of which Obtaining blood for analysis of various circulating biomarkers is the first listed.
NCT05743049 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05743049 about?
NCT05743049 is a clinical study titled "Collection of Circulating Biomarkers in Pancreatic Cancer". This protocol will involve collection of blood samples from patients with a diagnosis of pancreatic adenocarcinoma for evaluation of circulating biomarkers.
What is the current status of trial NCT05743049?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2023-02-27. Estimated completion is 2028-01-15.
What conditions does trial NCT05743049 study?
This clinical trial studies the following conditions: Pancreas Cancer.
What interventions are being tested in trial NCT05743049?
The interventions under investigation include: Obtaining blood for analysis of various circulating biomarkers (OTHER).
Who is sponsoring clinical trial NCT05743049?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05743049 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreas Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05743049's enrollment target sits among peer trials
30 41st of 54 higher than 13 of 54 other Pancreas Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreas Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
RECRUITING
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
The Cancer of the Pancreas Screening-5 CAPS5)Study
RECRUITING · Phase 3
-
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI